Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab

Manini1, Mariana Bueno; Matsunaga1,2, Natasha Yumi; Gianfrancesco1,2, Lívea; Oliveira1,2, Marina Simões; Carvalho3, Maria Rosa Vieira de; Ribeiro3, Gisleine Leila Martins Tengler; Morais3, Eliane de Oliveira; Ribeiro4, Maria Angela Gonçalves O.; Morcillo5, André Moreno; Ribeiro2,5, José Dirceu; Toro2,5, Adyléia Aparecida Dalbo Contrera

doi:10.36416/1806-3756/e20210157

6145
Views

Back to summary

Open Access

Peer-Reviewed
Artigo Original

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab

Fatores de risco para sibilância recorrente em crianças pré-termo que receberam profilaxia com palivizumabe

Mariana Bueno Manini1, Natasha Yumi Matsunaga1,2, Lívea Gianfrancesco1,2, Marina Simões Oliveira1,2, Maria Rosa Vieira de Carvalho3, Gisleine Leila Martins Tengler Ribeiro3, Eliane de Oliveira Morais3, Maria Angela Gonçalves O. Ribeiro4, André Moreno Morcillo5, José Dirceu Ribeiro2,5, Adyléia Aparecida Dalbo Contrera Toro2,5

DOI: 10.36416/1806-3756/e20210157

How to cite this article

Manini1 MB, Matsunaga1 NY, 2 , Gianfrancesco1 L, 2 , Oliveira1 MS, et al. Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab. J Bras Pneumol. 2021;47(5):e20210157